account_id none on file
legal_name Humacyte, Inc.
ticker HUMA
cik 1818382
domain humacyte.com
linkedin_company_url https://www.linkedin.com/company/humacyte/
entry_point_account_id none on file
name Humacyte Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 10 executives 0 family 0
why_nownone on file
callsnone on file
filings
We estimate net savings due to the workforce reductions and operating cost reductions, net of termination severance and benefits, totaling approximately $14.3 million.
filing / Aug 12, 2026 / receipt
In April 2025, the Company implemented a cost reduction action to reduce its workforce by 30 employees, cease recruitment of additional planned new hires, and reduce other operating expenses.
filing / Aug 12, 2026 / receipt
Employee severance costs associated with this action were $ 0.7 million, which were expensed during the second quarter of 2025.
filing / Aug 12, 2026 / receipt
There are no further costs associated with this cost reduction action expected to be incurred in the future. In May 2026, the Company implemented a plan to reduce its workforce by approximately 45 employees, defer additional planned new hires, and reduce other operating expenses.
filing / Aug 12, 2026 / receipt
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2026.
filing / Aug 12, 2026 / receipt
We estimate net savings due to the workforce reductions and operating cost reductions, net of termination severance and benefits, totaling approximately $14.3 million during the remainder of 2026.
filing / May 13, 2026 / receipt
On April 28, 2025, the Company implemented a cost reduction action to reduce its workforce by 30 employees, cease recruitment of additional planned new hires, and reduce other operating expenses.
filing / May 13, 2026 / receipt
Employee severance costs associated with this action were $ 0.7 million, which were expensed during the second quarter of 2025.
filing / May 13, 2026 / receipt
There are no further costs associated with this cost reduction action expected to be incurred in the future. Legal Matters From time to time, the Company may be involved in various lawsuits, claims, assessments and proceedings, including securities, commercial, intellectual property, product liability, contractual, governmental, employment or other matters that arise in the normal course of business.
filing / May 13, 2026 / receipt
Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2026.
filing / May 13, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-11 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug humacyte-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$